A recent research letter published in JAMA Pediatrics reported that the majority of patients with multisystem inflammatory syndrome in children (MIS-C) in a United Kingdom cohort had good outcomes with no significant medium- or long-term symptoms one year later. The Aug. 30 report included data for 68 patients admitted to the hospital before May 2020 who were followed until April 2021.
“This one-year follow-up study of patients with MIS-C is encouraging,” said Adriana Tremoulet, MD, MAS, a professor of pediatrics in the University of California-San Diego’s Department of Pediatrics and Rady Children’s Hospital and a specialist in Kawasaki disease, who was not involved with the research. Media coverage of the findings included articles by Medscape, Healio and the McClatchy News Service.
“Additional studies such as Long-Term Outcomes after the Multisystem Inflammatory Syndrome in Children (MUSIC) study will provide further clarity as to the long-term implications of MIS-C,” Dr. Tremoulet noted. “Now in the time of a COVID vaccine, it is clear more than ever that vaccinating eligible children and adults is the best way to prevent MIS-C. I am grateful to all of my colleagues who continue to educate their patients and the public about the COVID vaccine, in the hopes that it will spare a family suffering from MIS-C.”